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MetaGxData: Clinically Annotated 
Breast, ovarian and pancreatic 
Cancer Datasets and their Use in 
Generating a Multi-Cancer Gene 
signature
Deena M. A. Gendoo  1, Michael Zon2,4, Vandana sandhu2, Venkata s. K. Manem2,3,5, 
Natchar Ratanasirigulchai2, Gregory M. Chen2, Levi Waldron  6 & Benjamin Haibe-
Kains2,3,7,8,9
A wealth of transcriptomic and clinical data on solid tumours are under-utilized due to unharmonized 
data storage and format. We have developed the MetaGxData package compendium, which includes 
manually-curated and standardized clinical, pathological, survival, and treatment metadata across 
breast, ovarian, and pancreatic cancer data. MetaGxData is the largest compendium of curated 
transcriptomic data for these cancer types to date, spanning 86 datasets and encompassing 
15,249 samples. Open access to standardized metadata across cancer types promotes use of their 
transcriptomic and clinical data in a variety of cross-tumour analyses, including identification of 
common biomarkers, and assessing the validity of prognostic signatures. Here, we demonstrate that 
MetaGxData is a flexible framework that facilitates meta-analyses by using it to identify common 
prognostic genes in ovarian and breast cancer. Furthermore, we use the data compendium to create 
the first gene signature that is prognostic in a meta-analysis across 3 cancer types. These findings 
demonstrate the potential of MetaGxData to serve as an important resource in oncology research, and 
provide a foundation for future development of cancer-specific compendia.
Ovarian, breast and pancreatic cancers are among the leading causes of cancer deaths among women, and recent 
studies have identified biological and molecular commonalities between them1–4. These cancers are part of hered-
itary syndromes related to mutations in a number of shared susceptibility genes that contribute to their carcino-
genesis, including BRCA1 and BRCA23,5. As evidenced by epidemiological and linkage analysis studies, mutations 
and allelic loss in the BRCA1 locus confers susceptibility to ovarian, pancreatic and early-onset breast cancer5–8. 
The BRCA2 gene appears to account for a proportion of early-onset breast cancer that is roughly equal to that 
resulting from BRCA15,8. BRCA2-mutation carriers with mutations within the ovarian cancer cluster region 
have been observed to exhibit greater risk for ovarian cancer5. In addition to common susceptibility genes, both 
tumours may express a variety of common biomarkers that include hormone receptors, epithelial markers (e.g., 
cytokeratin 7, Ber-EP4), growth factor receptors (Her2/neu) and other surface molecules3.
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Commonalities between breast, ovarian, and pancreatic cancers have been observed not only for specific 
susceptibility genes, but at system-wide levels as well. In particular, molecular profiling across transcriptomes, 
copy-number landscapes, and mutational patterns emphasize strong molecular commonalities between basal-like 
breast tumours, high-grade serous ovarian cancer (HG-SOC), and basal-like pancreatic adenocarcinomas 
(PDACs)2,9,10. The growing list of parallels between Basal-like breast cancer, HG-SOC and basal-like PDACs 
include high frequency of TP53 mutations and TP53 loss, chromosomal instability, and widespread DNA copy 
number changes2,9–11. Statistically significant subsets of both Basal-like breast tumors and HG-SOC also share 
BRCA1 inactivation, MYC amplification, and highly correlated mRNA expression profiles2,9. Subtype-specific 
prognostic signatures also reveal strong similarities between prognostic pathways in basal-like cancer and ovarian 
cancer, while ER-negative and ER-positive breast cancer subtypes exhibit different prognostic signatures12. These 
ongoing studies promote identification of shared prognostic and predictive biomarkers across multiple cancer 
subtypes for future treatment.
Continuous growth of publicly available databases of breast, ovarian and pancreas genome-wide profiles 
necessitates the development of large-scale computational frameworks that can store these complex data types, 
as well as integrate them for meta-analytical studies. Current bioinformatics initiatives provide extensive data 
repositories for microarray data retrieval and annotation of specific tumour types. These resources enable anal-
ysis of single datasets, but do not provide sufficient standardization across independent studies of single or mul-
tiple cancer types13–19 that are necessary for meta-analysis or other holistic analyses. This poses a challenge for 
meta-analytical investigations that aim to address global patterns across multiple forms of cancer, including for 
example, building multi-cancer gene signatures that generalize to new data9,20,21. Identifying robust prognos-
tic signatures from transcriptomic data remains a major obstacle9,12,21, and requires large sample sizes that can 
only be provided by large-scale meta-analysis20,22–26. Additionally, most gene signatures derived from a single or 
small set of datasets are not generalizable to new data. In our recent systematic validation of ovarian signatures, 
primarily built from single datasets, we demonstrated that the concordance index of the best ovarian signatures 
only ranged from 0.54 to 0.5827, whereas signatures trained by meta-analysis could improve significantly on this 
performance28. The resulting standardized database of ovarian cancer profiles29 enabled numerous subsequent 
meta-analyses and the development of statistical methodology. Efforts to standardize analyses of the transcrip-
tomes of multiple cancer types have focused on coupling microarray repositories with graphical user interfaces to 
allow researchers to address targeted biologic questions on collective transcriptome datasets30–32; however, these 
tools lack the generality to apply novel and potentially complex analyses.
An integrative framework is thus needed to harness the breadth of transcriptomic and clinical data from 
multiple cancer types, and to serve as a resource for integrative analysis across these aggressive cancer types. 
There are growing efforts towards the development of curated and clinically relevant microarray repositories 
for breast cancer, ovarian cancer, and pancreatic cancer data4,29,33–36. These studies provide a solid foundation 
for the development of a controlled language for clinical annotations and standardized transcriptomic data rep-
resentation across the three cancer types. Here, we have developed the MetaGxData package compendium, which 
includes manually-curated and standardized clinical, pathological, survival, and treatment metadata for breast, 
ovarian, and pancreatic cancer transcriptome data. MetaGxData is the largest, standardized compendium of 
breast, ovarian and pancreas microarray datasets to date, spanning 86 datasets and encompassing 15,249 sam-
ples. Standardization of metadata across these cancer types promotes the use of their expression and clinical data 
in a variety of cross-tumour analyses, including identification of common biomarkers, establishing patterns of 
common co-expressed genes across cancer types, assessing the validity of prognostic signatures, and identifica-
tion of new consensus signatures that reflects upon common biological mechanisms. In this paper, we present 
our flexible framework, unified nomenclature, as well as applications that demonstrate the analytical power of 
integrative analysis of a large number of breast, ovarian, and pancreatic cancer transcriptome datasets. As an 
example of its application, we integrated breast and ovarian cancer data to develop a multi-cancer gene signature 
and assessed its prognostic value in pancreatic cancer, demonstrating the existence of a multi-cancer prognostic 
gene signature.
Results
MetaGxData characterization and curation. The MetaGxData compendium integrates three packages 
containing curated and processed expression datasets for breast (MetaGxBreast), ovarian (MetaGxOvarian), 
and pancreatic (MetaGxPancreas) cancers. Our current framework extends upon the standardized framework 
we had already generated for curatedOvarianData29. Our proposed enhancements facilitate rapid and consist-
ent maintenance of our data packages as newer datasets are added, and provides enhanced user-versatility in 
terms of data rendering across single or multiple datasets. All of these datasets can be downloaded through 
the MetaGxBreast, MetaGxOvarian and MetaGxPancreas R data packages publicly available through the 
Bioconductor ExperimentHub37–39. Vignettes outlining how to access the MetaGxBreast, MetaGxOvarian and 
MetaGxPancreas datasets in R are available through the Bioconductor website.
We developed semi-automatic curation scripts to standardize gene and clinical annotations of our breast, 
ovarian and pancreatic cancer datasets based on the nomenclature used in The Cancer Genome Atlas (TCGA) 
(Supplementary File S1)2,29. At its core, the MetaGxData compendium represents a unified pipeline for processing 
datasets within a given form of cancer, and providing cancer-specific data packages to users with standardized 
gene and clinical annotations (Fig. 1). Such annotations include a host of relevant categorical variables that reflect 
upon tumour histology (stage, grade, primary site, etc.), as well as categorical and numerical variables crucial 
for survival analysis and prognostication in these cancers (including overall survival, recurrence-free survival, 
distant-free survival, and metastasis-free survival) (Supplementary Fig. S2). Most importantly, we have provided 
a number of comparable and overlapping clinicopathological features across breast, ovarian and pancreatic can-
cer samples, such as age at diagnosis, tumour grade, or vital status (Fig. 2). Where some datasets lack vital status 
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or other endpoints, we have included information on other endpoints, such as relapse free survival (breast and 
ovarian cancer datasets) and distant metastasis free survival (breast cancer datasets only). Additional common 
variables between the datasets can be seen in the supplementary figures (Supplementary Figs S3–S5). We also 
provide tumour-specific and critical annotations for each tumour type, including, for example, biomarker iden-
tification status (HER2, ER, PR) in breast cancer, and TNM status for pancreatic datasets. Treatment information 
across the cancers is provided when available.
For subsequent analyses presented in this work, overall survival was used as the primary endpoint, and data-
sets lacking vital status were excluded from the analysis. For pancreatic cancer, survival information was obtained 
exclusively using overall survival as the primary endpoint.
Analysis of prognostic genes in breast, ovarian, and pancreatic cancer. The wealth and breadth 
of transcriptomic datasets in MetaGxData can be used as a framework for translational cancer research. As an 
example of the versatility of our packages, we conducted a meta-analysis of the prognostic value of well-studied 
prognostic genes in ovarian cancer and pancreatic cancer, as well as our previously published gene modules 
in breast cancer using the MetaGxBreast, MetaGxPancreas and MetaGxOvarian packages (Figs 3–5)22,23,27,28. A 
total of 6 ovarian genes (PTCH1, TGFBR2, CXCL14, POSTN, FAP, and NUAK1), 36 pancreas genes from the 
gene signature developed by Haider et al.40, and 7 breast cancer gene modules (ESR1, ERBB2, STAT1, CASP3, 
PLAU, VEGF, and AURKA) were tested. For breast cancer gene modules, each module is comprised of a set of 
highly-correlated genes (using Gram-Schmidt variable selection) relating to specific cancer biological processes 
that we previously demonstrated to have prognostic utility in breast cancer23,28. For simplicity, each module is 
identified by a standard ‘prototype gene’; as an example, the ‘AURKA’ module contains genes that are highly cor-
related with the proliferation gene AURKA (Fig. 3a).
The hazard ratio of tested genes and gene modules was determined by calculating the D.index, which is an 
estimate of the log hazard ratio (HR) comparing two equal sized groups. We observed that the direction of hazard 
ratios of these genes (HR > 1 or HR < 1) was fairly consistent, largely deviated from HR = 1, and was statistically 
significant across datasets. Genes with hazard ratios closer to 1 demonstrated greater variability in the direction 
Figure 1. Diagrammatic representation of the data processing pipeline for packages that are part of the 
MetaGxData compendium. Depicted are the processes involved in downloading a dataset, and standardization 
of molecular (gene) and clinical (patient) data to produce cancer-specific compendia that abide by the 
MetaGxData framework.
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of the HR index across datasets, owing to their decreased prognostic relevance (Fig. 3a). Furthermore, log rank 
tests were used to determine whether splits in the survival curves generated by using the genes to group patients 
into high and low score groups were statistically significant.
Unsurprisingly, higher gene expression levels of the proliferation gene AURKA indicate poorer survival in 
breast cancer (log rank p = 1.1e-16, n = 4,161) (Fig. 3c). This supports previous findings regarding the impor-
tance of this gene in biology-driven signatures of breast cancer, and its comparable prognostic effect with other 
multi-gene prognostic signatures22,23,35,41,42. We have also observed that the NUAK1 gene exhibits worst prog-
nosis in ovarian cancer (log rank p = 6.2e-9, n = 2,450) (Fig. 4c). We have previously demonstrated the utility 
of NUAK1 in the development of a debulking signature that can predict the outcome of cytoreductive surgery28. 
Figure 5 demonstrates the results of the 6 top-most statistically significant genes from the Haider et al. pancreatic 
gene signature40. Of these genes, we have observed that adrenomedullin (ADM) exhibits the worst prognosis in 
pancreatic cancer (Fig. 5c). High expression levels of ADM led to poor outcomes in patients, which is consistent 
with previous findings that ADM is over expressed in PDAC and enhances pancreatic cancer cell invasion43.
Meta-analysis of gene expression prognosis across cancers. Our single-gene prognostic analysis can 
easily be extended to a genome-wide meta-analysis across individual cancer types, or combining several cancer 
types. To this end, we first determined the prognostic capability of 22,410 genes that are common across predom-
inantly female cancers (Supplementary File S6). We identified 30 genes that are significantly prognostic across 
both tumours (False Discovery Rate [FDR] < 5%). From this list of prognostic genes, we subsequently identified 
12 genes that share same-direction hazard ratios in both breast and ovarian cancers: 3 genes have elevated expres-
sion values indicative of worse prognosis in both cancers (HR > 1), and 9 genes have better prognosis (HR < 1) 
(Supplementary File S6). Such analyses can be used to test pan-cancer hypotheses across much larger sample sizes 
than previously possible, and will allow deeper study of relationships between cancer subtypes.
We additionally conducted a genome-wide analysis of all the genes present across the MetaGxPancreas data-
sets in order to identify highly prognostic genes (Supplementary File S6). Only genes present in at least 6 of 
the 12 datasets containing overall survival information were considered in the search for the most prognostic 
genes (n = 19,245 genes). The 3 genes that led to the poorest outcomes when overexpressed (largest HR) with 
FDR-adjusted p-values under 5% were FAM83A (HR = 1.83), HMGA2 (HR = 1.73), and KRT7 (HR = 1.72). The 
3 genes whose expression was most indicative of better outcomes (smallest HR), with an FDR-adjusted p-values 
under 5% were PPP1R10 (HR = 0.69), FRZB (HR = 0.7), and GATA6 (HR = 0.71), and FAM189A2 (HR = 0.68). 
Notably, FAM189A2 was also identified in our analysis as the only gene that is indicative of worse outcome 
(FDR < 0.05, HR < 1) across breast, ovarian, and pancreatic cancers (Supplementary File S6).
Figure 2. Schematic representation of some of the common clinical variables (pData) that are available across 
datasets in MetaGxBreast, MetaGxOvarian, and MetaGxPancreas. The Stacked bar plots indicate the percentage 
of samples in every dataset annotated with a particular variable designation. Continuous numeric values are 
represented by box plots.
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MetaGx gene signature creation and prognosis in breast, ovarian and pancreatic cancer. We 
developed a gene signature that is prognostic in both breast and ovarian cancers by running a single-gene, 
genome-wide prognostic analysis on 22,410 genes as above, but excluding several large breast and ovarian data-
sets for use as validation cohorts. The METABRIC dataset (n = 2136 samples) from MetaGxBreast, and 5 of the 
largest ovarian datasets (GSE9891, GSE32062, GSE49997, GSE26712, GSE51088) were removed from the analysis 
for later use as the validation cohort to test the signature. Using only the training sets, meta-analysis identi-
fied 53 genes with significant hazard ratios in both cancers (FDR < 5%, HR > 1.125 or HR < 0.875), which were 
used to form the MetaGx signature (Table 1). The direction of association of the genes comprising the signature 
was chosen based on the hazard ratios (HR > 1 positive direction). Notably, the MetaGx signature included 3 
genes (DDB2, GSTZ1, and FAM1892A) that had been previously identified from the set of 12 genes sharing 
same-direction hazard ratios in the meta-analysis of breast and ovarian cancers (Supplementary File S6).
The top 5 signatures from our recent review of ovarian gene signatures were evaluated alongside the MetaGx 
signature, and each signature was tested in the molecular subtypes identified by The Cancer Genome Atlas 
Research Network (immunoreactive, proliferative, mesenchymal, differentiated subtypes)1,27. The MetaGx sig-
nature was the most prognostic of the ovarian signatures tested in an analysis containing all the patients (HR 
2.02, n = 1,069) and was the only signature providing statistically significant prognostic capabilities within each 
subtype (log rank tests p < 0.05). Although the D index was prognostic in the differentiated subtype (HR 1.85, 
n = 427) and the most prognostic of the signatures tested in the Mesenchymal subtype (HR 1.95, n = 229), the 
MetaGx signature did not yield statistically significant D indices in the immunoreactive and proliferative subtypes 
(Fig. 6a–e).
In breast cancer, the MetaGx signature was benchmarked against the clinically relevant mammaprint and 
oncotype DX signatures44–46. Our three gene (ER, HER2, and AURKA) subtype classification model (SCM) was 
Figure 3. Assessment of the prognostic value of seven key gene modules in breast cancer, using the 
MetaGxBreast package. (a) Heatmap representation of hazard ratios for each gene module, across 9 datasets. 
The estimate is presented as a hazard ratio for each gene. Ratios greater than 1 (red) indicate worse prognosis 
for elevated expression levels of that gene in the respective datasets. (b) Random effects meta-estimates of the 
hazard ratios for each gene, calculated by pooling the hazard ratios from each individual dataset. (c) Kaplan-
Meier curves of the most prognostic gene with p < 0.05, in this case AURKA. Each KM plot represents patients 
of a specific treatment type. Within each plot, patients are split into ‘high’ and ‘low’ based on the median 
AURKA score.
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chosen to classify patients into the ER+/HER2−, ER−/HER2−, and HER2+ subtypes35. The MetaGx signature 
was highly prognostic in the analysis using all patients (HR 1.60, n = 1,971) (Fig. 6f) and had the largest D index 
in the ER−/HER2− subtype (HR 1.61, n = 393) (Supplementary Fig. S7).
We further tested the prognostic value of the MetaGx signature in pancreatic cancer and benchmarked it 
against pancreatic signatures from the literature. A signed average approach was implemented for evaluation, 
where the direction of association of the genes comprising the signature were chosen based on the hazard ratios 
(HR > 1 positive direction)40,47–49. Briefly, in each patient, genes from the signature whose expression led to poor 
outcomes (HR > 1) were added together, and genes whose expression led to a favorable prognosis (HR < 1) were 
subtracted. Accordingly, higher signature scores (ie, signed average) were associated with poorer outcomes. 
Information pertaining to the genes comprising each of the pancreatic signatures can be found in Supplementary 
File S8.
Of the 5 signatures tested, the MetaGx signature was the most prognostic in the analysis of all the patients (HR 
1.64, n = 903) and was the only signature that yielded a statistically significant difference in survival within both 
the basal (log rank p = 1.1e-3, n = 375) and the classical (log rank p = 1.3e-2, n = 528) pancreatic cancer molecu-
lar subtypes identified by Moffitt et al. (Table 2, Fig. 6j–l)50.
We determined the spearman correlation between patients signature scores and our gene modules in order 
to investigate the biological processes present in our signature (Supplementary Fig. S9). In all 3 cancers, the sig-
nature scores had strong positive spearman correlations with the PLAU module (0.67 in pancreas, 0.40 in breast, 
0.69 in ovarian) and relatively strong negative correlations with the ESR1 module (−0.51 in pancreas, −0.52 in 
breast, −0.35 in ovarian). Recent studies have shown that most published gene signatures often perform no better 
than 1,000 random signatures of equal length. To test this observation, the MetaGx signature was tested in the 
Figure 4. Assessment of the prognostic value of six key genes in ovarian cancer, using the MetaGxOvarian 
package. (a) Heatmap representation of hazard ratios for each gene, across 17 datasets. The estimate is presented 
as a hazard ratio for each gene. Ratios greater than 1 (red) indicate worse prognosis for elevated expression 
levels of that gene in the respective datasets. (b) Random effects meta-estimates of the hazard ratios for each 
gene, calculated by pooling the hazard ratios from each individual dataset. (c) Kaplan-Meier curves of NUAK1. 
Each KM plot represents patients of a specific tumour grade. Within each plot, patients are split into ‘high’ and 
‘low’ based whether they fall above or below the median NUAK1 gene expression. The asterisks above the D 
indices indicate whether the D index was statistically significant (p < 0.05).
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pancreatic cancer, ovarian cancer and breast cancer test datasets against 1,000 random signatures of equal size51. 
In all three cases, the magnitude of the hazard ratio from the MetaGx signature was larger than the random sig-
natures’ hazard ratio (p = 0.001 for all three cancers) (Supplementary Fig. S10).
Discussion
Meta-analysis of multiple cancer types is an area of high interest, with ongoing research continually supporting 
the growing relationship between these malignancies and suggesting common patterns of tumour biology52. We 
provide an integrative, standardized, and comprehensive platform to facilitate analysis between breast, ovarian, 
and pancreatic cancer. This platform provides a flexible framework for data assimilation and unified nomencla-
ture, with standardized data packages hosting the largest compendia of breast, ovarian, and pancreatic cancer 
transcriptomic and clinical datasets available to date.
Integration of genomic data into standardized frameworks is challenged by the inconsistency of the clinical 
curations across datasets and across tumour types. Annotation of clinicopathological variables may vary widely 
due to different protocols in different laboratories, institutions, and across international boundaries. We have 
standardized, as much as possible, the catalog of clinical variables within each tumour type. For characteristics 
pertaining to a specific tumour type, including ER, PGR, and HER2 IHC status in breast cancer samples, we have 
generated a semantic positive/negative variable to reflect IHC status. This facilitates searching across all patients 
irrespective of the original assay annotations that may have binary, numeric, or qualitative. Similarly, a binary var-
iable has been assigned to ovarian cancer patients to reflect whether they had been treated with platinum, taxol, 
or neoadjuvant therapy. Many of the annotated variables (ex: stage and tumour grade in MetaGxOvarian) have 
also been standardized to facilitate comparisons across multiple studies. Further analyses using our previously 
developed packages (curatedOvarianData) have indicated good consistency across datasets, and ultimately facili-
tated uniform and consistent investigations on the prognostic effect of biomarkers in ovarian cancer survival53,54.
The scale of MetaGxData facilitates identification of gene signatures that are prognostic across multiple forms 
of cancer. Using this compendium, we developed a gene signature that is prognostic for breast, ovarian, and 
pancreatic cancers. Requiring genes to be prognostic across multiple datasets should help distinguish between 
general and disease-specific processes affecting patient survival, and allow signatures to generalize better to new 
datasets, as opposed to conventional signature creation methods that select genes based on cox proportional 
Figure 5. Assessment of the prognostic value of genes in pancreatic cancer, using the MetaGxPancreas package. 
(a) Heatmap representation of hazard ratios for each gene, across 11 datasets. The estimate is presented as a 
hazard ratio for each gene. Ratios greater than 1 (red) indicate worse prognosis for elevated expression levels 
of that gene in the respective datasets. (b) Random effects meta-estimates of the hazard ratios for each gene, 
calculated by pooling the hazard ratios from each individual dataset. (c) Kaplan-Meier curve of ADM.
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Gene Symbol Description Entrez ID Direction
1 ACKR3 atypical chemokine receptor 3 57007 1
2 ACTN4 actinin alpha 4 81 1
3 ARHGAP21 Rho GTPase activating protein 21 57584 1
4 C12orf49 chromosome 12 open reading frame 49 79794 1
5 CACNB3 calcium voltage-gated channel auxiliary subunit beta 3 784 1
6 CAMK1D calcium/calmodulin dependent protein kinase ID 57118 1
7 CAMSAP3 calmodulin regulated spectrin associated protein family member 3 57662 −1
8 CBFB core-binding factor beta subunit 865 1
9 CDC37L1 cell division cycle 37 like 1 55664 −1
10 CDK19 cyclin dependent kinase 19 23097 1
11 CLDN4 claudin 4 1364 1
12 CMBL carboxymethylenebutenolidase homolog 134147 1
13 COP1 COP1, E3 ubiquitin ligase 64326 1
14 CRABP2 cellular retinoic acid binding protein 2 1382 1
15 CSE1L chromosome segregation 1 like 1434 1
16 DARS2 aspartyl-tRNA synthetase 2, mitochondrial 55157 1
17 DDB2 damage specific DNA binding protein 2 1643 −1
18 DPP4 dipeptidyl peptidase 4 1803 1
19 EGFR epidermal growth factor receptor 1956 1
20 FAM189A2 family with sequence similarity 189 member A2 9413 −1
21 GSTZ1 glutathione S-transferase zeta 1 2954 −1
22 IMPDH1 inosine monophosphate dehydrogenase 1 3614 1
23 IRF3 interferon regulatory factor 3 3661 1
24 KATNAL1 katanin catalytic subunit A1 like 1 84056 1
25 KIF11 kinesin family member 11 3832 1
26 LATS2 large tumor suppressor kinase 2 26524 1
27 LOXL2 lysyl oxidase like 2 4017 1
28 MOCS1 molybdenum cofactor synthesis 1 4337 −1
29 MREG melanoregulin 55686 −1
30 MSC musculin 9242 1
31 MYADM myeloid associated differentiation marker 91663 1
32 MYLK3 myosin light chain kinase 3 91807 −1
33 NAE1 NEDD8 activating enzyme E1 subunit 1 8883 1
34 NID2 nidogen 2 22795 1
35 OPRM1 opioid receptor mu 1 4988 1
36 PLAU plasminogen activator, urokinase 5328 1
37 PPEF1 protein phosphatase with EF-hand domain 1 5475 1
38 PWP1 PWP1 homolog, endonuclein 11137 1
39 RALY RALY heterogeneous nuclear ribonucleoprotein 22913 1
40 RARRES3 retinoic acid receptor responder 3 5920 −1
41 REX1BD required for excision 1-B domain containing 55049 1
42 SERPINB2 serpin family B member 2 5055 1
43 SIPA1L2 signal induced proliferation associated 1 like 2 57568 1
44 STK3 serine/threonine kinase 3 6788 1
45 TERF2 telomeric repeat binding factor 2 7014 1
46 TEX261 testis expressed 261 113419 1
47 TGFBI transforming growth factor beta induced 7045 1
48 TNFRSF18 TNF receptor superfamily member 18 8784 −1
49 TPD52L2 tumor protein D52 like 2 7165 1
50 UTP6 UTP6, small subunit processome component 55813 1
51 ZFAND2A zinc finger AN1-type containing 2 A 90637 1
52 ZNF204P zinc finger protein 204, pseudogene 7754 −1
53 ZSCAN32 zinc finger and SCAN domain containing 32 54925 −1
Table 1. Genes present in the MetaGx gene signature.
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hazard models in a single dataset. We have demonstrated that the multi-cancer MetaGx signature outperformed 
the top ovarian signatures identified in our previous review in an analysis conducted on all patients with overall 
survival as the endpoint. It was also more prognostic than the clinically-relevant Mammaprint and OncotypeDX 
signatures in the ER−/HER2− breast cancer subtype, and more prognostic than pancreas-specific signatures 
in pancreatic cancer. Furthermore, it was the only signature that was prognostic in each molecular subtype of 
pancreatic cancer, and was highly prognostic in the basal-like subtype. Notably, the MetaGx signature was not 
prognostic in the HER2− breast subtype or the immunoreactive and proliferative ovarian subtypes. One pos-
sible explanation for this behavior is that the number patients with those subtypes are fewer, compared to the 
majority of patients that were used to as the training set. This is particularly true for the Her2− subtype in breast 
cancer (n = 236 Her2− patients, in a training set of n = 1,969 breast cancer patients). However, we are unaware 
of any gene signature to-date that is prognostic across each subtype based on a meta-analysis of multiple datasets. 
Indeed, the clinically used Mammaprint signature, as an example, is only used for ER+/Her2− patients.
The large number of datasets offered as part of MetaGxData provides researchers with the ability to select dif-
ferent datasets for their respective analyses. As such, it is conceivable that researchers may select particular data-
sets to highlight the significance of signatures. However, the magnitude of the samples and datasets provided by 
the compendium makes it arguably difficult for researchers to justify why some datasets have been retained and 
others dismissed. In the current literature, many existing publications have derived prognostic signatures based 
on a comparison of 3–5 datasets. With the release of the MetaGxData, researchers now need to develop signatures 
that harness the full compendium. Hopefully, this will result in the production of more rigorous signatures, as 
these signatures would need to be prognostic across an entire meta-analysis.
To our knowledge, the MetaGx signature represents the first signature demonstrated to be prognostic in a 
meta-analysis across three cancers. This includes pancreatic cancer, which had been selected as an independent 
validation set for testing the signature. Our signature predicts poor outcomes associated with metastases for 
patients, based on our observations that patients signature scores across all three cancers consistently had strong 
positive correlations with our PLAU tumor metastases module. Furthermore, since the signature was consistently 
negatively correlated with the ESR1 module in all three cancers, and high signature scores led to poor outcomes, 
we believe the signature also models the poor outcomes associated with increased ER pathway activity in patients. 
Our signature provides additional support for the role of CLDN4 in pancreas, breast and ovarian malignancies. 
Higher expression levels of this gene placed patients in the high score group that had poorer outcomes in all 3 of 
these cancers. This is in agreement with numerous studies that have shown CLDN4 to be overexpressed in pan-
creatic, ovarian, and breast tumors relative to normal tissue55–59. It is also interesting to observe that FAM189A2 
Figure 6. Survival curves for the MetaGx signature with patients stratified by molecular subtypes. (a–e) 
Survival curves in ovarian cancer. (f–i) Survival curves in breast cancer. (j–l) Survival curves in pancreatic 
cancer. The asterisks above the D indices indicate whether the D index was statistically significant (p < 0.05).
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was one of the top genes across all 3 cancer that was indicative of worse outcomes when expression levels were low 
(HR < 1), which is consistent with what has been shown in lung and thyroid cancer60,61.
In conclusion, the MetaGxBreast, MetaGxOvarian and MetaGxPancreas packages follow a unified framework 
that facilitates integration of oncogenomic and clinicopathological data. We have demonstrated how our packages 
facilitate easy meta-analysis of gene expression and prognostication in breast, ovarian and pancreatic cancer. We 
have also demonstrated that leveraging this data in meta-analysis can lead to gene signatures that outperform 
clinically relevant breast signatures in ER−/HER2− patients, and outperform ovarian signatures developed from 
single datasets, as well as a number of published pancreatic cancer signatures. These packages have the potential 
to serve as an important resource in oncology and methodological research and provide a foundation for future 
development of cancer-specific compendia.
Methods
Breast cancer data acquisition. Breast cancer datasets were extracted from our previous meta-analysis of 
breast cancer molecular subtypes, which includes 39 microarray datasets from a variety of commercially avail-
able microarray platforms published from 2002 to 201435. Additional datasets were extracted from the Gene 
Expression Omnibus (GEO) and manually curated. Gene expression and clinical annotation for Metabric were 
downloaded from EBI ArrayExpress and combined into a dataset of 2,136 samples62. The cgdsr R package was 
used to extract 1,098 tumour samples from The Cancer Genome Atlas (TCGA), and matching clinical anno-
tations for these samples were downloaded from the TCGA Data Matrix portal (https://tcga-data.nci.nih.gov/
tcga/)2,63. Combining these studies produced a total of 39 breast cancer microarray expression datasets spanning 
10,004 samples. Of these 10,004 samples, survival information is available for 6,847 patients, including overall 
survival (n = 4,425), metastasis free survival (n = 2,695), and relapse free survival (n = 1,858).
ovarian cancer data acquisition. Ovarian microarray expression datasets were obtained from our recent 
update of the curatedOvarianData data package, onto which we have added 5 expression datasets to the originally 
published version29, for a total of 26 microarray datasets spanning 3,526 samples. To obtain these datasets we first 
used the curatedOvarianData pipeline to generate the “FULLcuratedOvarianData” version of the package, which 
differs from the public version in that probe sets for same gene are not merged (https://bitbucket.org/lwaldron/
curatedovariandata). Of the 3,526 samples, survival information is available for 2,726 patients, including overall 
survival (n = 2,712) and relapse free survival (n = 1,928).
pancreatic cancer data acquisition. Pancreatic ductal adenocarcinoma (PDAC) datasets were obtained 
by curating datasets available from the literature. A total of 21 datasets were curated for a total of 1,719 patient 
transcriptomic profiles. Of the 21 datasets, overall survival data was present for 12 studies. Consequently, of the 
1,719 samples survival information is available for 1,000 patients, including overall survival (n = 1,000) and no 
relapse free survival data.
processing of gene expression datasets. The processing of breast and ovarian cancer microarray 
datasets was previously described29,35. The pancreatic cancer datasets were processed in the manner described 
within the original studies from which they were obtained; the only exception is the Kirby dataset, which had 
Gene Signature - Subtype D Index D Index 95% CI D Index P Log Rank Test P
1 MetaGx - All Patients 1.64 (1.37, 1.90) 1.9e-04 2.3e-06
2 MetaGx - basal 1.75 (1.31, 2.19) 1.1e-02 1.1e-03
3 MetaGx - classical 1.43 (1.09, 1.77) 3.7e-02 1.3e-02
4 Newhook PLos onea - All Patients 1.22 (0.97, 1.47) 1.1e-01 1.2e-01
5 Newhook PLos onea - basal 1.01 (0.80, 1.23) 9e-01 7.9e-01
6 Newhook PLos onea - classical 0.99 (0.77, 1.20) 9e-01 6.2e-01
7 Haider Gen Medb - All Patients 1.56 (1.23, 1.88) 6.8e-03 4.7e-06
8 Haider Gen Medb- basal 1.22 (0.88, 1.57) 2.4e-01 2.2e-01
9 Haider Gen Medb - classical 1.43 (1.15, 1.71) 1e-02 9.5e-02
10 Grutzmann Oncogenec - All Patients 1.35 (1.22, 1.49) 1.3e-05 2.1e-06
11 Grutzmann Oncogenec - basal 1.29 (0.91, 1.67) 1.7e-01 7.8e-03
12 Grutzmann Oncogenec - classical 1.23 (1.01, 1.46) 6.2e-02 1.1e-01
13 Stratford PLos medd - All Patients 1.39 (1.09, 1.68) 2.9e-02 6.3e-03
14 Stratford PLos medd - basal 1.22 (1.01, 1.43) 6.4e-02 2.6e-01
15 Stratford PLos medd- classical 1.29 (0.94, 1.63) 1.4e-01 6.7e-02
Table 2. Prognostic value of Pancreatic Cancer Gene Signatures. aT. E. Newhook et al., A thirteen-gene 
expression signature predicts survival of patients with pancreatic cancer and identifies new genes of interest, 
PLoS One, vol. 9, no. 9, p. e105631, Sep. 2014. bS. Haider et al., A multi-gene signature predicts outcome in 
patients with pancreatic ductal adenocarcinoma, Genome Med., vol. 6, no. 12, p. 105, Dec. 2014. cR. Grutzmann 
et al., Meta-analysis of microarray data on pancreatic cancer defines a set of commonly dysregulated genes, 
Oncogene, vol. 24, no. 32, pp. 5079–5088, Jul. 2005. dJ. K. Stratford et al., A six-gene signature predicts survival 
of patients with localized pancreatic ductal adenocarcinoma, PLoS Med., vol. 7, no. 7, p. e1000307, Jul. 2010.
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been aligned using Kallisto and whose expression values are calculated using the logarithm of the transcripts per 
kilobase million (TPM).
Across all datasets, we used GEO platform descriptions as the primary source of probe and gene annotations 
when available, otherwise original annotations as published by the authors were used for non-standard gene 
expression profiling platforms. The full set of gene annotation platforms across all expression sets can be found 
in the metadata files associated with each Bioconductor package, and is additionally provided in Supplementary 
Tables S11–S13. Gene symbols and Entrez Gene identifiers that matched the probeset ids of a given expression 
set were subsequently saved as part of the featureData (fData) pertaining to that expression set. For genes with 
multiple probesets, the iqr function within R was used to calculate the variance of the probes across the dataset; 
only the probe with the highest variance across the dataset was used to calculate the prognostic value of the gene. 
Standardization of gene expression values (normalization) across datasets was undergone using a meta-analysis 
(each gene is evaluated in each dataset, and a final estimate was determined for each gene via the survcomp 
comb.est function. Further details are provided below).
MetaGxData package implementation. The breast, ovarian, and pancreatic cancer datasets are available 
through the MetaGxBreast, MetaGxOvarian, and MetaGxPancreas R data packages hosted on Bioconductor’s 
ExperimentHub. The MetaGxData packages allow users to select and filter the finalized curated datasets using the 
loadOvarianDatasets, loadBreastDatasets and loadPancreasDatasets functions of MetaGxOvarian, MetaGxBreast 
and MetaGxPancreas, respectively. Users are provided options for filtering samples based on clinical parameters, 
availability of survival data, and sample replicates (patients with highly correlated transcriptomic profiles; spear-
man correlation > 0.98). Users are also provided other options including, but not limited to, the ability to remove 
datasets based on the number of samples and the number of survival events present in the data. Importantly, users 
have the ability to specifically select for only primary tumour samples or several tissue types (primary tumours, 
healthy tissue, etc.) using the sample type info found in the clinical data.
Collectively, our data compendium, referred to as MetaGxData, encompasses 86 processed datasets, con-
taining in total 15,249 breast, ovarian and pancreas samples. Information pertaining to the platform, number of 
samples, number of probes, and number of unique genes present in the breast, ovarian, and pancreas datasets can 
be found in in the supplementary files (Supplementary Tables S11, S12 and S13). Expression datasets are repre-
sented as SummarizedExperiment objects with attached clinical data (pData), and feature data (fData) and can be 
loaded into R with a single function call allowing for fast and flexible analysis38. Hosting the datasets within the 
Bioconductor ExperimentHub facilitates rapid integration of new datasets into the existing framework and allows 
for easy extension of newer studies into the package in future iterations of MetaGxData.
prognostication of breast and ovarian cancer genes and signature generation. Cox proportional 
hazards analysis was performed using the R package survcomp (version 1.29.4) to estimate the prognostic value 
(hazard ratio) and significance (corresponding p-value) of the genes in each dataset64. In these analyses, overall 
survival was used as the primary endpoint when determining the hazard ratio. After determining the hazard 
ratio in each dataset, a final combined estimate of the hazard ratio was calculated using a random-effects model 
(combine.est from survcomp)65. Expression data from non-tumor samples was removed from all analyses. When 
stratifying samples into groups to generate survival curves, samples within each dataset were stratified into two 
groups based on the median expression of the gene or the median gene signature/module score for all the samples 
within that dataset. For the gene signatures, risk prediction scores were determined using the signed average of 
the patients’ gene expression, with the sign being determined as their direction of association with the survival 
outcome (HR > 1 positive direction). Datasets which did not include the 3 genes in our SCM gene subtype clas-
sification model were removed from the survival analyses. For example, the UNC4 breast cancer dataset was 
excluded, as the ER probe was deemed poor quality by the manufacturer and removed from the annotations. 
Furthermore, the ICGCSEQ dataset in MetaGxPancreas was excluded, due to overlap of a subset of patients 
with the ICGCMICRO dataset. To generate the MetaGx gene signature, the aforementioned analysis was per-
formed on common genes in MetaGxBreast and MetaGxOvarian to determine the hazard ratios of each gene. 
The METABRIC dataset (n = 2136 samples) from MetaGxBreast, and 5 of the largest ovarian datasets (GSE9891, 
GSE32062, GSE49997, GSE26712, GSE51088, totaling 1,116 samples) were removed from the analysis for later 
use as the validation cohort to test the signature. The 53 genes with significant hazard ratios in both cancers 
(FDR < 5% and HR > 1.125 or FDR < 5% and HR < 0.875) were selected for the MetaGx gene signature.
Correlation between the signature scores and gene modules. Correlations between the MetaGx 
signature and the gene modules were determined by finding the individual Spearman correlations coefficients 
between the signatures risk predictions, and the gene modules risk predictions in each individual dataset. A 
meta-estimate for the correlation coefficient was then determined from the individual correlation coefficients and 
their associated standard errors via the survcomp package (combine.est function) using a random effects model.
statistical analysis. The hazard ratios were computed via the R survcomp package as D indices by using risk 
predictions for the signatures along with the patients’ corresponding survival times and overall survival statuses. 
The D-index is a robust estimate of the traditional Cox’s hazard ratio, more precisely an estimate of the hazard 
ratio comparing two equal-sized prognostic groups64,66. This is a scale-free measure of separation between two 
independent survival distributions under the proportional hazards assumption. All individual estimates were 
combined into a meta-estimate via survcomp in a random effects model to obtain a single best estimate of the D 
index; this metric is reported throughout the present work. The patient groups, survival times and overall survival 
status of the patients from all the datasets were used within the survival package to generate Kaplan-Meir survival 
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curves and determine the log-rank test p values67. D index and log-rank test p values below 0.05 were considered 
to be statistically significant. All analyses were conducted using R.
Data Availability
The datasets used in this manuscript are all publicly available for download through R Bioconductor’s Experimen-
tHub (https://bioconductor.org/packages/release/data/experiment/). The breast, ovarian, and pancreas datasets can 
be found in MetaGxbreast, MetaGxOvarian, and MetaGxPancreas, respectively. All the code required to reproduce 
the single-gene prognosis analysis, as well as the genome-wide meta-analysis and signature results, is publicly avail-
able on the CodeOcean (https://codeocean.com, analysis at https://codeocean.com/capsule/6438633/). The Code-
Ocean contains an executable version of the code, in the form of a standalone docker, that can be used to generate all 
of the results in the present work. This work complies with the guidelines outlined in68–70.
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